JP2024510666A5 - - Google Patents
Info
- Publication number
- JP2024510666A5 JP2024510666A5 JP2023557691A JP2023557691A JP2024510666A5 JP 2024510666 A5 JP2024510666 A5 JP 2024510666A5 JP 2023557691 A JP2023557691 A JP 2023557691A JP 2023557691 A JP2023557691 A JP 2023557691A JP 2024510666 A5 JP2024510666 A5 JP 2024510666A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- composition according
- talazoparib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163165723P | 2021-03-24 | 2021-03-24 | |
| US63/165,723 | 2021-03-24 | ||
| US202163282163P | 2021-11-22 | 2021-11-22 | |
| US63/282,163 | 2021-11-22 | ||
| US202263317368P | 2022-03-07 | 2022-03-07 | |
| US63/317,368 | 2022-03-07 | ||
| PCT/IB2022/052536 WO2022200982A1 (en) | 2021-03-24 | 2022-03-21 | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510666A JP2024510666A (ja) | 2024-03-08 |
| JP2024510666A5 true JP2024510666A5 (enExample) | 2025-03-31 |
Family
ID=80952181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557691A Pending JP2024510666A (ja) | 2021-03-24 | 2022-03-21 | Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240180906A1 (enExample) |
| EP (1) | EP4313034A1 (enExample) |
| JP (1) | JP2024510666A (enExample) |
| KR (1) | KR20230159510A (enExample) |
| AU (2) | AU2022244439A1 (enExample) |
| BR (1) | BR112023018906A2 (enExample) |
| CA (1) | CA3214316A1 (enExample) |
| MX (1) | MX2023011294A (enExample) |
| WO (1) | WO2022200982A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| SI2656842T1 (sl) | 2006-03-27 | 2016-10-28 | The Regents Of The University Of California | Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji |
| WO2007127010A2 (en) | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| EP2620432A3 (en) | 2007-10-26 | 2013-12-18 | The Regents Of the University of California | Diarylhydantoin compounds |
| CN104478875B (zh) | 2008-08-06 | 2017-04-12 | 麦迪韦逊科技有限公司 | 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 |
| SG173837A1 (en) | 2009-02-24 | 2011-09-29 | Medivation Prostate Therapeutics Inc | Specific diarylhydantoin and diarylthiohydantoin compounds |
| US8710086B2 (en) | 2009-04-09 | 2014-04-29 | Medivation Technologies, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof |
| EP2485804A4 (en) | 2009-10-07 | 2015-07-29 | Medivation Technologies Inc | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| EP2531033A4 (en) | 2010-02-03 | 2013-07-31 | Biomarin Pharm Inc | POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES |
| KR101826652B1 (ko) | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | 디히드로피리도프탈라지논 유도체의 합성 방법 |
| KR20190120458A (ko) | 2010-10-21 | 2019-10-23 | 메디베이션 테크놀로지즈 엘엘씨 | 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염 |
| CN105916846A (zh) | 2013-11-07 | 2016-08-31 | 麦迪韦逊科技有限公司 | 用于合成经保护的n-烷基三唑甲醛的三唑中间体 |
| EA201790290A1 (ru) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
| SG11201803462PA (en) | 2015-10-26 | 2018-05-30 | Medivation Tech Llc | Treatment of small cell lung cancer with a parp inhibitor |
| HUE060460T2 (hu) * | 2017-04-13 | 2023-03-28 | Janssen Pharmaceutica Nv | Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére |
| CA3078806A1 (en) * | 2017-10-13 | 2019-04-18 | Merck Patent Gmbh | Combination of a parp inhibitor and a pd-1 axis binding antagonist |
-
2022
- 2022-03-21 WO PCT/IB2022/052536 patent/WO2022200982A1/en not_active Ceased
- 2022-03-21 EP EP22713055.6A patent/EP4313034A1/en active Pending
- 2022-03-21 KR KR1020237035680A patent/KR20230159510A/ko active Pending
- 2022-03-21 CA CA3214316A patent/CA3214316A1/en active Pending
- 2022-03-21 MX MX2023011294A patent/MX2023011294A/es unknown
- 2022-03-21 US US18/283,634 patent/US20240180906A1/en active Pending
- 2022-03-21 BR BR112023018906A patent/BR112023018906A2/pt unknown
- 2022-03-21 JP JP2023557691A patent/JP2024510666A/ja active Pending
- 2022-03-21 AU AU2022244439A patent/AU2022244439A1/en not_active Abandoned
-
2025
- 2025-07-30 AU AU2025210784A patent/AU2025210784A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024510666A5 (enExample) | ||
| JP2023513015A (ja) | 異常な細胞成長を処置するための併用療法 | |
| CN103945849B (zh) | 癌症的联合治疗 | |
| US20200147080A1 (en) | Methods and compositions for treating abnormal cell growth | |
| CN116056699A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| US20230201198A1 (en) | Methods of treating abnormal cell growth | |
| JP2022510410A5 (enExample) | ||
| JP2002535249A (ja) | 腫瘍を治療する放射線療法及びｃｏｘ−２阻害剤の組合せ療法。 | |
| AU2018380174A1 (en) | Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JP2003533485A5 (enExample) | ||
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| WO2019094053A1 (en) | Disulfiram and copper salt dosing regimen | |
| JP2024502446A5 (enExample) | ||
| CN120659606A (zh) | 治疗转移性去势抵抗性前列腺癌的他拉唑帕尼及恩杂鲁胺的组合 | |
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| AU2021255084B2 (en) | Breast cancer therapeutic agent | |
| JP2022543679A5 (enExample) | ||
| US11000518B2 (en) | Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer | |
| CN112638385B (zh) | 用于治疗脑肿瘤的喹啉衍生物 | |
| JP2011513396A (ja) | プロトンポンプ阻害剤の使用により腫瘍細胞成長を阻害するための方法 | |
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| Hahn et al. | Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer | |
| CN116322690A (zh) | 组合的药物抗癌疗法 | |
| US20260041676A1 (en) | Combination Therapy | |
| CN110613713B (zh) | 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤 |